Table S1. Clinical characteristics of the patientsâ cohort. Samples from 42 patients were available for the analysis; among these, clinical data from 40 patients were available and retrospectively collected. (DOCX 22 kb
Figure S1. Result of EGFR E746_A750del in CSF cells of Patient #12 by ddPCR system. Y-axis means the...
Overview of the 483 genes present in the Illumina cancer gene panel. (XLSX 14 kb
Figure S1. Result of sanger sequencing. (A) Eleven mutations which were sanger sequenced. (B) - (H) ...
Table S4. Molecular details of EGFR mutational assessment in the cohort of 42 NSCLC patients. Result...
Table S3. Cut-off assessment of T790M determination on FFPE tissues by ddPCR. Results on 22 normal F...
Table S2. List of genes and genomic coordinates of the corresponding hotspots covered by Oncomineâ˘...
Figure S1. Correlation between amount of total cfDNA yields (pg/mL) and EGFR-activating mutated alle...
Figure S3. Integrative Genomic Viewer visualization of C797S and C797G resistance mutations in cis c...
Figure S2. Waterfall plot of target lesions shrinkage. The patients receiving osimertinib based upon...
Figure S1. Patients population. Of 531 patients without any treatment before surgery, 415 (78%) were...
Figure S3. Molecular profiles of EGFR compound mutations. (A) In patients with the G719X compound mu...
Figure S2. EGFR uncommon mutations detected by targeted sequencing. All the uncommon EGFR mutations ...
Table S1. Clinicopathological features of six patients with non-small cell lung cancer. Table S2. Ef...
Materials and methods. Table S1. Patient demographics and clinical characteristics. Table S2. Concen...
Clinical and treatment characteristics of the 18 cases with no ctDNA alterations detected. Table S2....
Figure S1. Result of EGFR E746_A750del in CSF cells of Patient #12 by ddPCR system. Y-axis means the...
Overview of the 483 genes present in the Illumina cancer gene panel. (XLSX 14 kb
Figure S1. Result of sanger sequencing. (A) Eleven mutations which were sanger sequenced. (B) - (H) ...
Table S4. Molecular details of EGFR mutational assessment in the cohort of 42 NSCLC patients. Result...
Table S3. Cut-off assessment of T790M determination on FFPE tissues by ddPCR. Results on 22 normal F...
Table S2. List of genes and genomic coordinates of the corresponding hotspots covered by Oncomineâ˘...
Figure S1. Correlation between amount of total cfDNA yields (pg/mL) and EGFR-activating mutated alle...
Figure S3. Integrative Genomic Viewer visualization of C797S and C797G resistance mutations in cis c...
Figure S2. Waterfall plot of target lesions shrinkage. The patients receiving osimertinib based upon...
Figure S1. Patients population. Of 531 patients without any treatment before surgery, 415 (78%) were...
Figure S3. Molecular profiles of EGFR compound mutations. (A) In patients with the G719X compound mu...
Figure S2. EGFR uncommon mutations detected by targeted sequencing. All the uncommon EGFR mutations ...
Table S1. Clinicopathological features of six patients with non-small cell lung cancer. Table S2. Ef...
Materials and methods. Table S1. Patient demographics and clinical characteristics. Table S2. Concen...
Clinical and treatment characteristics of the 18 cases with no ctDNA alterations detected. Table S2....
Figure S1. Result of EGFR E746_A750del in CSF cells of Patient #12 by ddPCR system. Y-axis means the...
Overview of the 483 genes present in the Illumina cancer gene panel. (XLSX 14 kb
Figure S1. Result of sanger sequencing. (A) Eleven mutations which were sanger sequenced. (B) - (H) ...